Oct 6, 2017

Study: Emphasizing a drug's side effects can trigger those effects

The "inexpensive" cream (on top) and "expensive" cream used in the study. Photo: Alexandra Tinnermann / Institute of Systems Neuroscience in Hamburg, Germany

Most people know about the placebo effect — when a person perceives, and then often receives, a beneficial health impact from a treatment that actually isn't directly addressing their condition. Studies have also shown people's perception of a higher-priced drug is that it will provide its remedy better.

Now, in a new study published Thursday, the flip side of that coin — called the nocebo effect — has been seen in people who reported worse side effects when given what they thought was a higher priced medicine.

Why this matters: "Understanding how nocebo effects work means that health care providers could actively use this knowledge in their way of talking to patients, how they explain things to patients and also which information to mention and to avoid in order to minimize the effect," one of the study authors, Alexandra Tinnermann, told Axios.

Study details: The team told 49 participants they were testing a prescription cream to relieve itch, and that one possible side effect was local skin sensitization, which could lead to increased pain perception. The group was divided into two groups — one to take an expensive-looking cream in a fancier box and the other to take a less expensive cream in a generic-looking box (both creams had no active ingredients).

The researchers then treated the participants with painful heat stimuli and recorded the neural activation in the brain and spinal cord.

Their findings: The participants who used the "expensive" cream reported a higher rate of pain that became more pronounced over time, compared to the participants using the "cheaper" cream. The researchers also determined the altered sensations due to perceived price were associated with differences in two particular brain regions (the periaqueductal gray and rostral anterior cingulate cortex).

Luana Colloca, a neuroscientist at the University of Maryland who was not part of this study, told Axios the study is interesting in how it shows the role the spinal cord and the two brain areas plays in switching pain on and off and the very real impact a person's perception can have on their pain levels.

"It's important [for clinicians and trial researchers] to know the words they use, the way they communicate, their behavior can raise perception of the side effects," says Colloca, who also wrote a perspective published with the study. She warned that in the past, misleading information about side effects led people to discontinue their treatment resulting in some of them dying from heart attacks or strokes.

Go deeper: Listen to a podcast of an interview with Tinnermann (at 10:01) and a YouTube video about the study.

Go deeper

The race to catch Nike's Vaporfly shoe before the 2020 Olympics

Illustration: Aïda Amer/Axios

Four months ago, on the very same weekend, Eliud Kipchoge became the first human to run a marathon in under two hours, and fellow Kenyan Brigid Kosgei shattered the women's marathon record.

Why it matters: Kipchoge and Kosgei were both wearing Nike's controversial Vaporfly sneakers, which many believed would be banned because of the performance boost provided by a carbon-fiber plate in the midsole that acted as a spring and saved the runner energy.

Go deeperArrow40 mins ago - Sports

Reassessing the global impact of the coronavirus

Illustration: Aïda Amer/Axios

Economists are rethinking projections about the broader economic consequences of the coronavirus outbreak after a surge of diagnoses and deaths outside Asia and an announcement from a top CDC official that Americans should be prepared for the virus to spread here.

What's happening: The coronavirus quickly went from an also-ran concern to the most talked-about issue at the National Association for Business Economics policy conference in Washington, D.C.

Tech can't remember what to do in a down market

Illustration: Rebecca Zisser/Axios

Wall Street's two-day-old coronavirus crash is a wakeup alarm for Silicon Valley.

The big picture: Tech has been booming for so long the industry barely remembers what a down market feels like — and most companies are ill-prepared for one.